MEDIPREN Drug Patent Profile
✉ Email this page to a colleague
When do Medipren patents expire, and when can generic versions of Medipren launch?
Medipren is a drug marketed by Mcneil and is included in two NDAs.
The generic ingredient in MEDIPREN is ibuprofen. There are sixty-four drug master file entries for this compound. Two hundred and thirty-nine suppliers are listed for this compound. Additional details are available on the ibuprofen profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Medipren
A generic version of MEDIPREN was approved as ibuprofen by STRIDES PHARMA on September 24th, 1986.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MEDIPREN?
- What are the global sales for MEDIPREN?
- What is Average Wholesale Price for MEDIPREN?
Summary for MEDIPREN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 208 |
| Patent Applications: | 4,149 |
| DailyMed Link: | MEDIPREN at DailyMed |
US Patents and Regulatory Information for MEDIPREN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mcneil | MEDIPREN | ibuprofen | TABLET;ORAL | 070475-001 | Feb 6, 1986 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Mcneil | MEDIPREN | ibuprofen | TABLET;ORAL | 071215-001 | Jun 26, 1986 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for MEDIPREN
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Recordati Rare Diseases | Pedea | ibuprofen | EMEA/H/C/000549 Treatment of a haemodynamically significant patent ductus arteriosus in preterm newborn infants less than 34 weeks of gestational age. |
Authorised | no | no | no | 2004-07-28 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
